Literature DB >> 19883757

Breast cancer aromatase expression evaluated by the novel antibody 677: correlations to intra-tumor estrogen levels and hormone receptor status.

Jürgen Geisler1, Takashi Suzuki, Hildegunn Helle, Yasuhiro Miki, Shuji Nagasaki, Nhat K Duong, Dagfinn Ekse, Turid Aas, Dean B Evans, Per E Lønning, Hironobu Sasano.   

Abstract

Breast cancer tissue estrogen levels on an average exceed plasma as well as benign breast tissue levels. To evaluate the contribution of intra-tumor aromatization to individual tumor estrogen levels (estradiol, E2; estrone, E1; estrone sulfate, E1S), breast cancer tissue sections obtained during mastectomy in 28 postmenopausal breast cancer patients were stained for aromatase protein expression using the aromatase antibody 677. The findings were correlated to intra-tumor estrogen levels determined with a highly sensitive HPLC-RIA. Staining with 677 alone (irrespective of the hormone receptor status) revealed no difference in tumor E2 levels comparing 677+ versus 677- tumors, although a non-significant trend towards higher tumor E1 and E1S levels was observed in 677+ breast cancers. In contrast, tumor levels of E(2) were significantly higher in ER+ tumors compared to ER- tumors (P<0.001) and to benign breast tissue from the same breast (P<0.001). Analysing the additional effect of positive staining with the aromatase antibody 677 on tumor estrogen levels in the subgroup of ER+ tumors, revealed significantly higher tumor levels of E2 (mean level of 544.7 versus 197.1 fmol/g tissue) as well as a non-significant trend concerning tumor E1 (mean level of 296.9 versus 102.1 fmol/g tissue). The mean tumor tissue E1S level was observed somewhat lower in ER+677+ (103.5 fmol/g) versus ER+677- tumors (190.1 fmol/g). In the subgroup of ER+PgR+ tumors, tissue levels of E2 were also found to be significantly higher among 677+ compared to 677- tumors: 873.2 fmol/g (95% CI 395.9-1925.6) versus 217.9 fmol/g (95% CI 88.8-534.9) (P=0.015). In conclusion, our results indicate a moderate effect of aromatase enzyme expression evaluated by IHC using the antibody 677 on intra-tumor estrogen levels among ER+ breast cancers. A substantial interindividual variation in the ratios between the individual estrogen fractions suggests additional effects, like alterations in other enzymes to be involved in the intra-tumor estrogen homeostasis. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19883757     DOI: 10.1016/j.jsbmb.2009.10.010

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  10 in total

1.  INSIGHTS ON AROMATASE IMMUNOHISTOCHEMISTRY: VARIATIONS BETWEEN INTRINSIC MOLECULAR SUBTYPES OF BREAST CANCERS.

Authors:  I Armasu; C Preda; V Ianole; V Mocanu; I Hristov; E C Andriescu; I Cretu-Silivestru; I Vasiliu; C G Dascalu; C D Lupascu; I Crumpei; D N Serban; I L Serban; D G Ciobanu Apostol
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Jan-Mar       Impact factor: 0.877

2.  Intratumoral estrogen concentration and expression of estrogen-induced genes in male breast carcinoma: comparison with female breast carcinoma.

Authors:  Kiyoshi Takagi; Takuya Moriya; Masafumi Kurosumi; Kimako Oka; Yasuhiro Miki; Akiko Ebata; Takashi Toshima; Shoji Tsunekawa; Hiroyuki Takei; Hisashi Hirakawa; Takanori Ishida; Shin-Ichi Hayashi; Junichi Kurebayashi; Hironobu Sasano; Takashi Suzuki
Journal:  Horm Cancer       Date:  2012-10-18       Impact factor: 3.869

Review 3.  Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole--of clinical importance?

Authors:  J Geisler
Journal:  Br J Cancer       Date:  2011-03-01       Impact factor: 7.640

4.  Preparation of a novel antiserum to aromatase with high affinity and specificity: Its clinicopathological significance on breast cancer tissue.

Authors:  Naoki Kanomata; Shiro Matsuura; Tsunehisa Nomura; Junichi Kurebayashi; Taisuke Mori; Jo Kitawaki; Takuya Moriya
Journal:  PLoS One       Date:  2017-05-10       Impact factor: 3.240

5.  Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC.

Authors:  Patricia A Young; Diana C Márquez-Garbán; Zorawar Singh Noor; Neda Moatamed; David Elashoff; Tristan Grogan; Tahmineh Romero; Hironobu Sasano; Ryoko Saito; Rebecca Rausch; Nalo Hamilton; Steven M Dubinett; Edward B Garon; Richard J Pietras
Journal:  JTO Clin Res Rep       Date:  2021-02-03

6.  Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Breast Cancer: A Network Meta-Analysis.

Authors:  Shanshan Chen; Lan Bo; Dan Lv; Fei Ma
Journal:  Breast Care (Basel)       Date:  2022-02-18       Impact factor: 2.268

7.  The Prognostic Impact of Intratumoral Aryl Hydrocarbon Receptor in Primary Breast Cancer Depends on the Type of Endocrine Therapy: A Population-Based Cohort Study.

Authors:  Helga Tryggvadottir; Emma Sandén; Sofie Björner; Alessandra Bressan; Maria Ygland Rödström; Somayeh Khazaei; Dean P Edwards; Björn Nodin; Karin Jirström; Karolin Isaksson; Signe Borgquist; Helena Jernström
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

8.  Initial Studies with 11C-Vorozole PET Detect Overexpression of Intratumoral Aromatase in Breast Cancer.

Authors:  Anat Biegon; Kenneth R Shroyer; Dinko Franceschi; Jasbeer Dhawan; Mouna Tahmi; Deborah Pareto; Patrick Bonilla; Krystal Airola; Jules Cohen
Journal:  J Nucl Med       Date:  2019-11-22       Impact factor: 11.082

Review 9.  The Regulation of Steroid Action by Sulfation and Desulfation.

Authors:  Jonathan W Mueller; Lorna C Gilligan; Jan Idkowiak; Wiebke Arlt; Paul A Foster
Journal:  Endocr Rev       Date:  2015-07-27       Impact factor: 19.871

10.  Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer.

Authors:  Erin D Giles; Sonali Jindal; Elizabeth A Wellberg; Troy Schedin; Steven M Anderson; Ann D Thor; Dean P Edwards; Paul S MacLean; Pepper Schedin
Journal:  Breast Cancer Res       Date:  2018-06-14       Impact factor: 6.466

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.